Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979601 | 0.98 | SIGMAR1 (0.49) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL7513389 | 0.90 | KEAP1 (0.48) | SIGMAR1TMEM97 | |
| SCHEMBL17219705 | 0.88 | ALOX15 (0.54) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL6656817 | 0.88 | SIGMAR1 (0.57) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL6659238 | 0.88 | SIGMAR1 (0.61) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL1306239 | 0.86 | ALOX15 (0.56) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL6660619 | 0.86 | SIGMAR1 (0.56) | SIGMAR1TMEM97ABCB1 | |
| SCHEMBL5841337 | 0.85 | SIGMAR1 (0.49) | SIGMAR1TMEM97 | |
| SCHEMBL7595350 | 0.85 | HRH3 (0.50) | — | |
| SCHEMBL6658589 | 0.83 | SIGMAR1 (0.51) | SIGMAR1TMEM97ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540338-B2 | Substituted cinnamic acid amides for treating pain | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2940003-A1 | CINNAMIC ACID AMIDE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| US-6444675-B2 | PROMOTING WEIGHT LOSS AND TREATING EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-03 | — | — | US | disclosed |
| EP-1202738-A4 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6432960-B2 | ANOREXOGENIC AGENTS TO PROMOTE WEIGHT LOSS AND TREAT EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-1202738-A1 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-20010049370-A1 | 4-Alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists | SIT SING-YUEN (US) | 2001-12-06 | — | — | US | disclosed |
| US-20010047002-A1 | Squarate derivatives of dihydropyridine NPY antagonists | SIT SING-YUEN (US) | 2001-11-29 | — | — | US | disclosed |
| WO-2001085098-A2 | SQUARATE DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085690-A1 | 4-ALKYL AND 4-CYCLOALKYL DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| US-6177429-B1 | SELECTIVE NEUROPEPTIDE Y (NPY) RECEPTOR ANTAGONISTS FOR PROMOTING WEIGHT LOSS AND TREATMENT OF EATING DISORDERS; ANOREXIGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-01-23 | — | — | US | disclosed |
| WO-2000078319-A1 | DIHYDROPYRAZINE DERIVATIVES AS NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | OPRL1, TRPV1, TRPA1 | SIGMAR1 262/4885TMEM97 1570/4885ABCB1 2758/4885 |
| US-20010047002-A1 | Squarate derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, SUCNR1 | SIGMAR1 1269/4885TMEM97 3423/4885ABCB1 4784/4885 |
| US-20010049370-A1 | 4-Alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists | NPY4R, NPY1R, NPY5R | SIGMAR1 489/4885TMEM97 2664/4885ABCB1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.